The glyburide report card

Abstract

Over the past decade, several studies have been published describing the use of glyburide for the treatment of women with gestational diabetes (GDM). These studies include randomized prospective trials, prospective studies, and cohort studies. With a total of more than 1000 patients, they encompass a wide range of patient populations and treatment centers and demonstrate the effectiveness of oral treatment in achieving good glycemic control in women with GDM. Taken together, these studies have demonstrated that glyburide is as safe and as useful as insulin for the treament of women with GDM and will likely become universally accepted as the first line drug of choice for treatment of this condition.

Gestational diabetes mellitus: Where are we now?

“…After 3-7 days, another dose of 5 mg in the evening can be added and thereafter, 5 mg increments to a maximum of 20 mg/day. If the patient does not achieve targeted levels of glycemic control, add long-acting insulin to the regimen or assign the patient to insulin therapy alone [63,64].…”

Gestational diabetes mellitus

“…3-7 gün sonra akşama 5 mg eklenir ve hedef değerler sağlanana kadar 5 mg'lık doz artışları ile maksimum 20 mg/gün dozuna kadar çıkı-labilir. Eğer bu dozlarda glisemik hedeflere ulaşıla-mazsa, tedaviye bazal insülin eklenmesi ya da oral ajan kesilerek insülin tedavisine başlanması gerekir (60,61). Son dönemde yapılan bir metaanalizde, gliburid ile neonatal hipoglisemi ve makrozomi risklerinin insüline göre daha fazla olduğu saptanmıştır (62).…”